Immunome Inc Reports Positive Phase 3 Trial Results for Varegacestat

Immunome Inc's stock surged by 27.75% in pre-market trading, reaching a 52-week high, as the broader market showed strength with the Nasdaq-100 up 0.54% and the S&P 500 up 0.47%.

The significant price movement is attributed to the positive results from Immunome's Phase 3 RINGSIDE trial for Varegacestat, which demonstrated an 84% reduction in the risk of disease progression or death in patients with progressing desmoid tumors. This success not only highlights the drug's efficacy but also positions it as a potential new standard of care, attracting increased investor interest amid the company's plans to submit a New Drug Application to the FDA in Q2 2026.

The implications of these results are profound for Immunome, as they validate the company's strategic positioning in oncology treatment and could unlock significant market opportunities. The positive trial outcomes are expected to bolster investor confidence and drive further interest in Immunome's innovative pipeline.